ATE534736T1 - Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen - Google Patents

Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen

Info

Publication number
ATE534736T1
ATE534736T1 AT05774134T AT05774134T ATE534736T1 AT E534736 T1 ATE534736 T1 AT E534736T1 AT 05774134 T AT05774134 T AT 05774134T AT 05774134 T AT05774134 T AT 05774134T AT E534736 T1 ATE534736 T1 AT E534736T1
Authority
AT
Austria
Prior art keywords
degenerative
compounds
treatment
inflammatory diseases
identification methods
Prior art date
Application number
AT05774134T
Other languages
German (de)
English (en)
Inventor
Reginald Brys
Nick Vandeghinste
Peter Tomme
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Application granted granted Critical
Publication of ATE534736T1 publication Critical patent/ATE534736T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489Metalloendopeptidases (3.4.24)
    • C12N9/6491Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/10Applications; Uses in screening processes
    • C12N2320/12Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486Metalloendopeptidases (3.4.24)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/101Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT05774134T 2004-06-14 2005-06-14 Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen ATE534736T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57930704P 2004-06-14 2004-06-14
PCT/EP2005/052754 WO2005121778A2 (en) 2004-06-14 2005-06-14 Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases

Publications (1)

Publication Number Publication Date
ATE534736T1 true ATE534736T1 (de) 2011-12-15

Family

ID=35503767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05774134T ATE534736T1 (de) 2004-06-14 2005-06-14 Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen

Country Status (7)

Country Link
US (3) US7306923B2 (enExample)
EP (4) EP1773997B1 (enExample)
JP (1) JP2008502355A (enExample)
AT (1) ATE534736T1 (enExample)
CA (1) CA2569511A1 (enExample)
MX (1) MXPA06014577A (enExample)
WO (1) WO2005121778A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485468B2 (en) * 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2007071048A1 (en) * 2005-12-22 2007-06-28 Jane Ennis Viable cells from frozen umbilical cord tissue
WO2008155397A2 (en) 2007-06-20 2008-12-24 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
CA2698812A1 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
US8450397B2 (en) * 2007-09-25 2013-05-28 Dunlop Sports Co. Ltd. Golf ball
DE102007059839A1 (de) 2007-12-11 2009-06-25 Harald Dipl.-Ing. Feuerherm Schlauchförmiger Vorformling und Herstellung blasgeformter Teile und Verfahren sowie Vorrichtung zur Herstellung des Vorformlings
KR101594202B1 (ko) * 2008-09-24 2016-02-15 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드. 세포 유착 방지를 위한 펩티드와 조성물 및 그것의 사용 방법
AU2015224504B2 (en) * 2008-12-29 2018-02-22 Tel Hashomer Medical Research, Infrastructure And Services Ltd Peptides and compositions for prevention of cell adhesion and methods of using same
ES2528133T3 (es) * 2008-12-29 2015-02-04 Tel Hashomer Medical Research, Infrastructure And Services Ltd. Péptidos y composiciones para prevención de la adhesión celular, y métodos para utilizar los mismos
US11174299B2 (en) 2008-12-29 2021-11-16 Dispersebio Ltd. Peptides and compositions for prevention of cell adhesion and methods of using same
WO2010115841A1 (en) * 2009-04-01 2010-10-14 Galapagos Nv Methods and means for treatment of osteoarthritis
US20150004189A1 (en) 2012-02-07 2015-01-01 La Jolla Institute For Allergy And Immunology Epitopes from allergen proteins and methods and uses for immune response modulation
US20160138027A1 (en) * 2013-03-14 2016-05-19 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
WO2019054922A1 (en) * 2017-09-13 2019-03-21 Alexera Ab METHODS OF IDENTIFYING THERAPEUTIC AGENTS THAT INTERACT WITH STK24
CN115190804A (zh) * 2020-01-14 2022-10-14 纽约市哥伦比亚大学理事会 通过重定向内源性去泛素化酶稳定靶向蛋白质的组合物和方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
WO2000014250A1 (en) 1998-09-09 2000-03-16 The Board Of Regents Of The University Of Oklahoma Tyrosylprotein sulfotransferase polypeptides and polynucleotides
AU2475899A (en) 1998-01-29 1999-08-16 Board Of Regents Of The University Of Oklahoma, The Tyrosylprotein sulfotransferase polypeptides and polynucleotides
ATE346147T1 (de) * 1998-02-13 2006-12-15 Wistar Inst Zusammensetzungen und methoden zur wundheilung
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20020151681A1 (en) * 1999-03-12 2002-10-17 Rosen Craig A. Nucleic acids, proteins and antibodies
US20050112118A1 (en) 1999-12-02 2005-05-26 Myriad Genetics, Incorporated Compositions and methods for treating inflammatory disorders
US7332337B2 (en) 2000-05-16 2008-02-19 Galapagos Nv Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US20020132823A1 (en) 2001-01-17 2002-09-19 Jiahuai Han Assay method
WO2002070744A2 (en) 2001-03-07 2002-09-12 Galapagos Genomics B.V. Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds
US6537780B2 (en) 2001-03-28 2003-03-25 Applera Corporation Isolated nucleic acid molecules encoding transferase enzymes
US6426221B1 (en) * 2001-08-01 2002-07-30 Isis Pharmaceuticals, Inc. Antisense modulation of RIP2 expression
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
JP2005522999A (ja) * 2002-01-31 2005-08-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 癌を処置するための方法および組成物
JP2006515165A (ja) * 2002-09-16 2006-05-25 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
WO2004041170A2 (en) * 2002-11-01 2004-05-21 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2513148A1 (en) * 2003-01-23 2004-08-05 Eirx Therapeutics Limited Kinases and gpcrs involved in apoptosis
WO2004092413A2 (en) * 2003-04-18 2004-10-28 Novartis Ag High throughput functional genomic screening methods for osteoarthritis
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
DE10328033A1 (de) 2003-06-19 2005-01-05 Bläß, Stefan, Dr. Verfahren und ArthritisChip zur Diagnostik, Verlaufskontrolle sowie zur Charakterisierung der rheumatoiden Arthritis und der Osteoarthrose
CA2533803A1 (en) * 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
US7485468B2 (en) * 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases

Also Published As

Publication number Publication date
EP2256198A1 (en) 2010-12-01
EP2256197A1 (en) 2010-12-01
WO2005121778A2 (en) 2005-12-22
US20090062137A1 (en) 2009-03-05
US7919259B2 (en) 2011-04-05
US20110118140A1 (en) 2011-05-19
US20060014184A1 (en) 2006-01-19
US7306923B2 (en) 2007-12-11
WO2005121778B1 (en) 2007-02-01
EP2270160A1 (en) 2011-01-05
WO2005121778A3 (en) 2006-11-23
MXPA06014577A (es) 2007-03-23
EP1773997B1 (en) 2011-11-23
CA2569511A1 (en) 2005-12-22
JP2008502355A (ja) 2008-01-31
EP1773997A2 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
ATE534736T1 (de) Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
DOP2005000040A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
UY28450A1 (es) Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos.
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
EP1841426A4 (en) ACTIVE TERTIARY CARBINAMINES WITH SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF ALZHEIMER DISEASE AS INHIBITORS OF BETA-SECRETASE
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
UY28279A1 (es) Fenacilo 2 -hidroxi - 3 - diaminoalcanos
PA8583601A1 (es) Derivados de pirrolidona como inhibidores de maob
UY28101A1 (es) Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer
UY28484A1 (es) Compuestos para el tratamiento de trastornos neurodegenerativos
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0610644B8 (pt) composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
NO20076405L (no) Anvendelse av 24-nor-UDCA
DE602004008658D1 (de) Behandlung neurodegenerativer krankheiten
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
MX2009012525A (es) Pirazol-pirrolidinas como inhibidores de gamma secretasa.
ATE422201T1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
EP1817312A4 (en) MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
ECSP088280A (es) Compuestos de imidazol para el tratamiento de trastornos neurológicos
UY28825A1 (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos
UY28458A1 (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.